Each TABLET contains:Fenproporex hydrochlorideequivalent a 20.0 mgfenproporex
It is indicated as an adjunct in the treatment of exogenous obesity, associated with a hypocaloric diet.
The fenproporex is a derivative of phenylisopropylamines acting on brain centers control -Ape -tito and specifically on the ascending reticular activating system, with drug levels within 30-60 minutes after ingestion, peaking at 2-4 hours with a duration of 6 to 8 hours.
The route of excretion is the kidney, much is excreted in the urine and the remainder excreted as metabolites with an average time of removal within 48 hours.
IFA deity * A.P. is contraindicated in patients with severe arterial hypertension, ischemic heart disease, renal failure, glaucoma, advanced arteriosclerosis, and in patients hypersensitive to fenproporex or idiosyncrasy to sympathomimetic amines, states of agitation or emotionally unstable individuals who are susceptible or history of drug or alcohol abuse.
The association with non-selective MAOIs is contraindicated since this may trigger paroxysmal hypertension or malignant hyperthermia due to the prolonged action of MAOIs.
This interaction is possible even 15 days after stopping the administration of MAOIs. In pregnancy and lactation.
- Must not exceed the recommended dose, however, the drug should be discontinued when the patient stops losing weight.
- Must be used with a high degree of caution in severe arterial hypertension, ischemic heart disease, renal failure, glaucoma and advanced arteriosclerosis.
RESTRICTIONS OF USE DURING PREGNANCY AND LACTATION
In the absence of experimental studies according to current regulations and increasing human clinical data, the risk is unknown, and consequently as a precautionary measure should not be prescribed fenproporex during pregnancy and lactation.
In some sensitive individuals may receive the following symptoms that may alter the normal behavior tachycardia, insomnia or excitation light, dry mouth, constipation.
DRUG INTERACTIONS AND OTHER GENDER
The fenproporex not be provided in partnership with other anorectics. Anorectics should not be associated with MAOIs.It is not advisable partnership with guanethidine and its derivatives, since this group of drugs produces abolition of the antihypertensive effect of guanethidine (guanethidine moving there from its neuronal site of action).
Avoid indirect sympathomimetic drugs or use other antihypertensive drugs.
Please consult your personal physician before taking any medication.